Stock Research for BMRN

BMRN

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

BMRN Stock Chart & Research Data

The BMRN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BMRN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


BMRN Due diligence Resources & Stock Charts

The BMRN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BMRN Detailed Price Forecast - CNN Money CNN View BMRN Detailed Summary - Google Finance
Yahoo View BMRN Detailed Summary - Yahoo! Finance Zacks View BMRN Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View BMRN Trends & Analysis - Trade-Ideas Barrons View BMRN Major Holders - Barrons
NASDAQ View BMRN Call Transcripts - NASDAQ Seeking View BMRN Breaking News & Analysis - Seeking Alpha
Spotlight View BMRN Annual Report - CompanySpotlight.com OTC Report View BMRN OTC Short Report - OTCShortReport.com
TradeKing View BMRN Fundamentals - TradeKing Charts View BMRN SEC Filings - Bar Chart
WSJ View Historical Prices for BMRN - The WSJ Morningstar View Performance/Total Return for BMRN - Morningstar
MarketWatch View the Analyst Estimates for BMRN - MarketWatch CNBC View the Earnings History for BMRN - CNBC
StockMarketWatch View the BMRN Earnings - StockMarketWatch MacroAxis View BMRN Buy or Sell Recommendations - MacroAxis
Bullish View the BMRN Bullish Patterns - American Bulls Short Pains View BMRN Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View BMRN Stock Mentions - StockTwits PennyStocks View BMRN Stock Mentions - PennyStockTweets
Twitter View BMRN Stock Mentions - Twitter Invest Hub View BMRN Investment Forum News - Investor Hub
Yahoo View BMRN Stock Mentions - Yahoo! Message Board Seeking Alpha View BMRN Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for BMRN - SECform4.com Insider Cow View Insider Transactions for BMRN - Insider Cow
CNBC View BMRN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BMRN - OTC Markets
Yahoo View Insider Transactions for BMRN - Yahoo! Finance NASDAQ View Institutional Holdings for BMRN - NASDAQ


Stock Charts

FinViz View BMRN Stock Insight & Charts - FinViz.com StockCharts View BMRN Investment Charts - StockCharts.com
BarChart View BMRN Stock Overview & Charts - BarChart Trading View View BMRN User Generated Charts - Trading View




Latest Financial News for BMRN


BioMarin to Host Second Quarter 2018 Financial Results Conference Call and Webcast on Thursday, August 2 at 4:30pm ET
Posted on Wednesday July 11, 2018

SAN RAFAEL, Calif. , July 11, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...


Gene Therapy: BioMarin, Spark Can Both Win Treating Hemophilia
Posted on Monday July 09, 2018

Gene therapy has been hailed as a potential breakthrough treatment for many diseases, and today Credit Suisse's Martin Auster takes a look at its future for hemophilia treatment. Auster writes that gene therapy could become a "foundational approach in hemophilia management," with important data points due out this summer from Spark Therapeutics (ONCE) Pfizer (PFE) that will "incrementally evolve the landscape." He writes that there are signs of high patient demand for new treatments, and that gene therapy could be a more cost-efficient way to improve poor outcomes for hemophilia patients in the emerging markets. The stakes are still high: Auster believes that if issues arise, "uptake would ultimately disappoint greatly," but if long-term safety and durability is established, he expects "broad adoption of gene therapy given convenience and economic benefits." Ultimately, he believes that in this environment, the binary debate of Spark versus BioMarin Pharmaceuticals (BMRN) isn't the full picture.


BioMarin Partners with Believe Limited for 'Breaking Through!' Musical Theater Intensive
Posted on Monday July 09, 2018

SAN RAFAEL, Calif., July 9, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) today announced an exclusive partnership with Believe Limited to produce the 'Breaking Through!' musical theater intensive. The first-of-its-kind program is a three-day music workshop for the bleeding disorders community and is designed to provide young adults with powerful education on the healing and therapeutic power of the arts and self-expression. The musical workshop, directed by hemophilia advocate and Believe Limited CEO Patrick James Lynch, will be held from November 9 – November 12, 2018 and will culminate in a Broadway-style performance for local bleeding disorder community members, family and friends.


Sarepta's DMD Portfolio Solid, Sole Drug Dependence Concerns
Posted on Thursday July 05, 2018

Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on a single product for near-term growth is a concern.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.